Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock
Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller’s Duquesne Family Office drew attention to the stock by buying 316,000 shares of Revolution in the first quarter. The move has paid off for Druckenmiller, as the stock is up more than 105% since…
Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller’s Duquesne Family Office drew attention to the stock by buying 316,000 shares of Revolution in the first quarter. The move has paid off for Druckenmiller, as the stock is up more than 105% since his purchase.
Revolution is a clinical-stage company that focuses on targeted therapies against RAS proteins to replace traditional chemotherapy in treating aggressive malignancies, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. The scientific community had regarded RAS proteins as undruggable because potential therapeutic agents struggled to bind their surfaces. However, Revolution successfully created druggable sites through its tricomplex inhibitor platform, thereby blocking cancer cell signaling.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Druckenmiller isn’t the only wealthy investor high on the stock, as BlackRock and Vanguard own significant shares of Revolution. Here are three likely reasons why.
Image source: Getty Images.
1. It’s about to leap from clinical to commercial
The company’s lead investigational drug, Daraxonrasib, achieved positive results in a phase III clinical trial targeting previously treated metastatic pancreatic cancer patients. The treatment group achieved a median survival of 13.2 months, compared with 6.7 months in the standard chemotherapy group, effectively doubling survival. Based on these final results, which have been submitted to support regulatory review applications, the Food and Drug Administration (FDA) granted the drug Breakthrough Therapy Designation and Orphan Drug Designation.
Revolution is nearing completion of its New Drug Application submission to the FDA. The European Medicines Agency also initiated an accelerated review procedure for Daraxonrasib this month, paving the way for a global launch. The drug is said to be worth $7 billion a year in sales.
Revolution is advancing late-stage clinical studies for Daraxonrasib across multiple indications. A phase III trial of the drug for non-small cell lung cancer is ongoing. Another candidate, Zoldonrasib, has entered phase III trials as a monotherapy for pancreatic cancer, with a combination trial alongside standard chemotherapy set to initiate soon. In colorectal cancer, the company is conducting early-stage studies and plans to announce the results of a combination study later this year.
2. The company has the funds to bring its top therapies to market
Because it has no products on the market, Revolution generates no revenue. Driven by high research and development expenses, the company’s first-quarter net income loss doubled year over year, exceeding $453 million. However, the company holds $1.9 billion in cash, which, combined with $2.1 billion from recent financing, provides strong support for ongoing clinical trials.
Rising development expenses are standard for clinical-stage biotechnology companies and do not signal financial trouble. Regulatory approval for Daraxonrasib would validate the company’s core technology platform, open new revenue streams, and establish a path toward profitability.
3. The company’s pipeline has wide-ranging applications
Unlike first-generation therapies that focus narrowly on inactive off states or single mutations, such as early KRAS G12C inhibitors, Revolution Medicines specializes in RAS(ON) inhibitors. Its lead candidates, Daraxonrasib and Zoldonrasi, bind directly to the protein’s active signaling state. This allows the therapies to target broad mutation profiles across pancreatic, non-small cell lung (NSCLC), and colorectal cancers, giving Revolution a significantly larger total addressable market than single-mutation competitors.
The high-value oncologic pipeline makes the company an attractive acquisition candidate for major pharmaceutical companies looking to replace revenue lost to upcoming patent cliffs.
An acceptable risk
Like any clinical-stage biotech stock, Revolution presents a significant risk to investors. After all, it has no approved therapies, and its share run-up this year makes it vulnerable to a drop at any hint of bad news, such as a trial setback, regulatory pushback, or the need for more funds.
As it is, the company’s net loss was $1.1 billion in 2025, meaning the stock, with a market value of around $40 billion, is priced for flawless execution of becoming a commercial entity.
However, it also has the potential to be a unique company with a differentiated pipeline that targets difficult-to-treat cancers. View this as a risky stock, but with considerable upside potential.
Should you buy stock in Revolution Medicines right now?
Before you buy stock in Revolution Medicines, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Revolution Medicines wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $386,727!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,232,139!*
Now, it’s worth noting Stock Advisor’s total average return is 906% — a market-crushing outperformance compared to 208% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 2, 2026.
James Halley has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BlackRock. The Motley Fool has a disclosure policy.
Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock was originally published by The Motley Fool
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
